Bluejay Diagnostics (BJDX) Cash from Investing Activities (2021 - 2026)
Bluejay Diagnostics (BJDX) reported Cash from Investing Activities of -$15314.0 for Q1 2026, down 1261.24% sequentially from -$1125.0 in Q4 2024.
Bluejay Diagnostics (BJDX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Bluejay Diagnostics (BJDX) has 5 years of Cash from Investing Activities data on file, last reported at -$15314.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$15314.0; the trailing twelve-month figure through Mar 2026 stood at -$286664.0 (changed N/A YoY), and the FY2025 full-year result was -$173735.0, up 43.37% from the prior year.
- Cash from Investing Activities retreated to -$15314.0 in Q1 2026, from -$1125.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$227.0 in Q3 2024 to a low of -$791464.0 in Q3 2022.
- A 4-year average of -$171194.8 and a median of -$87894.0 in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities sank 18392.15% in 2022 and surged 99.7% in 2024, its largest moves.
- Tracing BJDX's Cash from Investing Activities over 4 years: stood at -$238207.0 in 2022, then soared by 63.1% to -$87894.0 in 2023, then jumped by 98.72% to -$1125.0 in 2024, then tumbled by 1261.24% to -$15314.0 in 2026.
- Business Quant data shows BJDX's Cash from Investing Activities at -$15314.0 in Q1 2026, -$1125.0 in Q4 2024, and -$227.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Bluejay Diagnostics | 1.07 Mn | 1.07 Mn | - | -15,314.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15,314.00 |
| Mar 31, 2026 | -15,314.00 |
| Dec 31, 2024 | -1,125.00 |
| Dec 31, 2024 | -1,125.00 |
| Sep 30, 2024 | -227.00 |
| Sep 30, 2024 | -227.00 |
| Jun 30, 2024 | -269,998.00 |
| Jun 30, 2024 | -269,998.00 |
| Mar 31, 2024 | -35,433.00 |
| Mar 31, 2024 | -35,433.00 |
| Dec 31, 2023 | -87,894.00 |
| Dec 31, 2023 | -87,894.00 |
| Sep 30, 2023 | -74,498.00 |
| Sep 30, 2023 | -74,498.00 |
| Jun 30, 2023 | -201,105.00 |
| Jun 30, 2023 | -201,105.00 |
| Mar 31, 2023 | -340,669.00 |
| Mar 31, 2023 | -340,669.00 |
| Dec 31, 2022 | -238,207.00 |
| Dec 31, 2022 | -238,207.00 |